VVOS

VVOS is a sub-$7M micro-cap whose balance sheet has crossed into distress. Stockholders' equity is negative (-$1.49M, down 118.7% YoY) as total liabilities exploded +264.3% to $26.7M against just $25.2M of assets. The near-term liquidity picture is the core of the call: $2.03M of cash (down 67.6%) sits against $8.35M of debt now current (+560.3%) and $18.1M of current liabilities versus only $4.38M of current assets — a current ratio near 0.24. With operating cash flow of -$15.3M in FY2025, the company burns roughly its entire cash balance every six-to-seven weeks, which is why shares outstanding jumped +129% in a year. The equity is effectively a residual claim being continuously diluted to fund losses; that is the definition of not-investable-now.

The income statement offers no offset. Yes, revenue grew +16% to $17.4M and gross margin is a respectable 60.4%, but the five-year history shows revenue essentially flat-to-lower since FY2021 ($16.9M) with a net loss that widened back to -$21.2M — worse than every year except FY2022. Operating margin is -114%. The R&D line of $100K (flat) tells you this is a commercialization struggle, not an R&D-stage biotech waiting on a catalyst. The problem is demand: management admits VIPs 'typically start slowly,' that there is a 'slow acceptance rate' and 'low concentration of active VIPs who regularly start new cases' — the very reason they abandoned the dental-practice model.